Quantcast

Latest Interferon beta-1a Stories

2009-03-30 07:00:00

- Supports US Drug Discovery Activities in Neurodegenerative Diseases- ROCKLAND, Mass., March 30 /PRNewswire/ -- EMD Serono, Inc. announced today that it will open a site in Cambridge, Massachusetts to support its growing Research function. The Cambridge laboratory space will accommodate EMD Serono's US drug discovery activities in neurodegenerative diseases such as multiple sclerosis (MS), which will augment the company's existing US research in oncology and fertility. EMD Serono expects...

2009-03-18 06:00:00

-- EMD Serono and Fast Forward agree to work together to speed research development on a select group of high potential MS research projects with support of up to $19 million in funding ROCKLAND, Mass. and NEW YORK, March 18/PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt Germany, and Fast Forward, LLC, a wholly-owned subsidiary of the National Multiple Sclerosis Society, today announced a collaborative partnership to evaluate and fund promising multiple sclerosis (MS)...

2009-02-24 08:00:00

SAN DIEGO, Feb. 24 /PRNewswire/ -- Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis. ARX424 was created by Ambrx through the application of its proprietary protein optimization technology, ReCODE(TM). This second collaboration between the two companies follows a previous agreement announced in 2007 to...

2009-02-04 07:00:00

Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States,...

2008-10-29 09:00:36

Theratechnologies (TSX: TH) and EMD Serono Inc., an affiliate of Merck KGaA , Darmstadt Germany, today announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all tesamorelin commercialization rights outside of the US. This announcement marks the end of the strategic review process initially...

69f96049fb2993a4f81399f887bdfe8d1
2008-10-23 15:56:08

A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday. Bayer AG and Genzyme Corp's alemtuzumab, marketed under the brand name Campath, showed long-term improvement in disability in a three-year study, said Alasdair Cole, a neurologist at the University of Cambridge. Multiple sclerosis is an autoimmune condition in which the immune system damages the central...

2008-10-23 12:00:00

Genzyme and Bayer have reported Phase II study results demonstrating the potential of alemtuzumab in treatment-naive MS patients. Although the product's efficacy is now established, two recently initiated Phase III trials will reveal whether alemtuzumab should be used as an early treatment or if safety issues will restrict it to patients who continue to relapse on currently approved MS therapies. Results from the final three-year analysis of the 334-patient CAMMS223 study showed that...

2008-10-23 06:00:27

By Rita Rubin A leukemia drug was about 70% more effective than a standard therapy in treating early multiple sclerosis, according to clinical trial results in today's New England Journal of Medicine. In multiple sclerosis, or MS, the immune system attacks myelin, the sheath that enables nerve cells to conduct impulses between the brain and other parts of the body. The drug, alemtuzumab, depletes the body of the white blood cells that attack myelin, which are eventually replaced by...

2008-10-22 18:00:09

Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif(R) (high-dose interferon beta-1a). Importantly, the mean disability of patients on alemtuzumab...

2008-09-24 12:00:37

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has announced that the ongoing Improve study met its primary endpoint. The primary objective of the Improve study was to evaluate the efficacy of the new formulation of Rebif, compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS) and active disease by means of magnetic resonance imaging (MRI) at the end of 16 weeks of treatment. The 16-week study results show that the mean number of combined unique...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related